Interventions specifically designed to target cachexia in patients with thoracic or gastrointestinal cancer and established cachexia were effective in helping patients preserve functional stability and rehabilitation potential.
Researchers assessed the efficacy of nabilone for improving symptoms of anorexia in patients with NSCLC. In addition, patient appetite, quality of life, and nutritional status were also assessed.
Data from 5 phase 2/3 studies demonstrate improved weight and body mass in patients with NSCLC receiving anamorelin.
Resistance Training, Nutritional Interventions Prevent Muscle Loss During, After Radiotherapy for Head and Neck CancerAugust 01, 2017
Intervention with resistance training and nutritional supplements during and after radiation therapy is not only feasible, but also shown to prevent loss of muscle mass and improve quality of life in patients with head and neck cancer (HNC).
Findings at 6 and 12 months after treatment for advanced head and neck cancer indicate a higher risk of recurrences for those reporting cachexia after their treatment.
[Clinical Medicine Insights: Oncology] A case study of a 49-year-old premenopausal woman with metastatic invasive ductal breast carcinoma in the vertebral and iliac bones, which progressed with new metastases to her hips, thigh bones, and vertebrae.
Loss of appetite and not eating are difficult aspects of cancer for patients' loved ones to understand. Continued and diligent nurse education can help both patients and families cope with this disturbing effect.
A new drug is proven to offer significantly better outcomes for patients with non-small cell lung cancer who experience this debilitating side effect.
A new drug, anamorelin, has been found to improve appetite and body mass in patients with advanced lung cancer who are experiencing cancer anorexia and cachexia.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|